Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.59 |
| ▸ | FEN1 | P39748 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4193217 | 0.89 | TP53 (0.61) | HPGD | |
| SCHEMBL15183798 | 0.88 | MEN1 (0.62) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4174579 | 0.88 | CYP1A1 (0.54) | HPGDLMNATSHR | |
| SCHEMBL29617015 | 0.87 | TP53 (0.62) | HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL5863231 | 0.86 | TP53 (0.56) | HPGDLMNAALDH1A1MAPK1MEN1 | |
| SCHEMBL2404818 | 0.86 | NPC1 (0.59) | HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL5943816 | 0.85 | ALDH1A1 (0.57) | ALDH1A1MAPK1KDM4ESMN1; SMN2 | |
| SCHEMBL2771575 | 0.85 | CA12 (0.62) | HPGD | |
| SCHEMBL13639694 | 0.85 | CDC25A (0.49) | HPGDLMNATSHR | |
| SCHEMBL7825137 | 0.84 | PLAU (0.66) | HPGDLMNATSHRERCC5FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184977-A1 | Nickel or Iron Catalysed Carbon-Carbon Coupling Reaction of Arylenes, Alkenes and Alkines | SALTIGO GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184977-A1 | Nickel or Iron Catalysed Carbon-Carbon Coupling Reaction of Arylenes, Alkenes and Alkines | SALTIGO GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184977-A1 | Nickel or Iron Catalysed Carbon-Carbon Coupling Reaction of Arylenes, Alkenes and Alkines | SALTIGO GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| WO-2007031511-A1 | NICKEL OR IRON CATALYSED CARBON-CARBON COUPLING REACTION OF ARYLENES, ALKENES AND ALKINES | SALTIGO GMBH (DE) | 2007-03-22 | — | — | WO | disclosed |
| US-5545645-A | Heterocyclic derivatives in the treatment of ischaemia and related diseases | SYNTEX PHARMACEUTICALS, LIMITED (GB) | 1996-08-13 | — | — | US | disclosed |
| EP-0693062-A1 | HETEROCYCLIC DERIVATIVES IN THE TREATMENT OF ISCHAEMIA AND RELATED DISEASES | SYNTEX PHARMACEUTICALS LTD. (GB) | 1996-01-24 | — | — | EP | disclosed |
| US-5428037-A | Piperazine derivatives; calcium and sodium channel antagonists | SYNTEX PHARMACEUTICALS, LTD. (GB) | 1995-06-27 | — | — | US | disclosed |
| WO-1994024116-A1 | HETEROCYCLIC DERIVATIVES IN THE TREATMENT OF ISCHAEMIA AND RELATED DISEASES | SYNTEX PHARMACEUTICALS LIMITED (GB) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184977-A1 | Nickel or Iron Catalysed Carbon-Carbon Coupling Reaction of Arylenes, Alkenes and Alkines | MON2, ZRANB2, GRIA2 | HPGD 3937/4885LMNA 3666/4885TSHR 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.